ADAPTIGENE Oncolytic Virus Platform

Based on research led by EpicentRx’s Chief Scientific Officer and UCSD Professor of Medicine, Tony Reid, the ADAPTIGENE oncolytic virus platform is designed to rally a powerful immune response against cancers. Enhanced with multiple bits of therapeutic DNA or transgenes, the platform primes the efficacy of already approved immunotherapy drugs and opens the door to promising combination treatments for aggressive and difficult-to-treat cancers. 

The first clinical program involves custom oncolytic viruses armed with immunostimulatory transgenes. The second program is personalized cancer vaccines equipped with patient-specific neoantigens.

EpicentRx’s personalized viral vaccines have been tested in the clinic under compassionate use, with Phase 1 trials expected in 2020.